FDA Releases Revised Guidance to Reduce Risk of Creutzfeldt-Jakob Disease Transmission from Blood and Blood Products

Summary

The Food and Drug Administration (FDA) has released a revised guidance document to minimize the risk of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) transmission from blood and blood products, building on previous recommendations and finalizing a draft guidance from 2001.